LATEST ASPIRIN NEWS:
March 2012 - Aspirin Link to Cancer Prevention - Video
ASPREE would like to thank SBS World News for permission to play this story on our website
March 2012 - Aspirin Link to Cancer prevention - Summary
January 2012 - Australia way ahead on aspirin warning
Promotional Video
Primary ethics site
Monash University Human Research Ethics Committee (MUHREC)
Secondary ethics sites
1. Royal Australian College of General Practitioners.
2. Human Research Ethics Committee (Tasmania) Network.
3. ACT Health Human Research Ethics Committee.
4. Goulburn Valley Health Ethics & Research Committee
Aspirin may help older people to live well for longer by delaying the onset of illnesses. In fact, previous studies have shown that low dose aspirin:
- Reduces the risk of heart attack, stroke and vascular events in middle aged people
- May help to prevent cognitive decline and forms of cancer such as bowel cancer
However, aspirin is known to have adverse-effects, such as bleeding, that may offset its benefits. Before doctors can know for sure if aspirin is helpful in prolonging healthy life in older people, the benefits must be weighed against the risks.
The ASPREE study, for the first time, will determine whether the potential benefits of aspirin outweigh the risks for people over age 70.
The Trial -
- ASPREE is a randomised, double-blind placebo controlled study
- It involves both males and females, 70 years and older
- Participants are randomly assigned (or randomised) to take either a low-dose aspirin tablet (100mg) or a placebo tablet (dummy pill) for a period of 5 years
- The study will recruit 19,000 healthy participants through regional centres (both in urban and rural locations throughout Australia and the United States)
- Annual follow-ups will involve a number of health, clinical and other measurements click here Any abnormalities will be reported to the participant’s doctor for further assessment